CRIS Current Research Information System

GIONCHETTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.064
AS - Asia 14.022
EU - Europa 10.097
SA - Sud America 950
Continente sconosciuto - Info sul continente non disponibili 935
AF - Africa 925
OC - Oceania 21
Totale 43.014
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.699
SG - Singapore 3.781
VN - Vietnam 3.703
CN - Cina 3.336
IT - Italia 2.235
GB - Regno Unito 2.019
DE - Germania 1.223
SE - Svezia 1.061
HK - Hong Kong 1.035
FR - Francia 708
BR - Brasile 701
IN - India 598
RU - Federazione Russa 574
UA - Ucraina 451
IE - Irlanda 410
KR - Corea 344
FI - Finlandia 322
NL - Olanda 292
JP - Giappone 276
ZA - Sudafrica 221
BD - Bangladesh 220
CI - Costa d'Avorio 207
TG - Togo 174
SC - Seychelles 169
CA - Canada 156
CH - Svizzera 145
BG - Bulgaria 138
EE - Estonia 130
JO - Giordania 120
AR - Argentina 116
PH - Filippine 98
BE - Belgio 74
MX - Messico 70
PL - Polonia 67
ID - Indonesia 64
IQ - Iraq 64
ES - Italia 61
TH - Thailandia 59
AT - Austria 54
HN - Honduras 44
TW - Taiwan 44
TR - Turchia 41
GR - Grecia 33
IR - Iran 32
SA - Arabia Saudita 32
EC - Ecuador 30
NG - Nigeria 29
PK - Pakistan 28
CD - Congo 27
CO - Colombia 27
UZ - Uzbekistan 27
CL - Cile 25
JM - Giamaica 20
PY - Paraguay 19
AU - Australia 18
BZ - Belize 18
EG - Egitto 16
KZ - Kazakistan 16
VE - Venezuela 16
CZ - Repubblica Ceca 15
LT - Lituania 15
RO - Romania 15
KE - Kenya 14
TN - Tunisia 13
AZ - Azerbaigian 12
HR - Croazia 12
MY - Malesia 12
AE - Emirati Arabi Uniti 11
CR - Costa Rica 11
LB - Libano 11
MA - Marocco 11
DZ - Algeria 10
ET - Etiopia 10
AL - Albania 8
BH - Bahrain 8
BO - Bolivia 7
IL - Israele 7
PS - Palestinian Territory 7
DO - Repubblica Dominicana 6
NI - Nicaragua 6
PR - Porto Rico 6
BB - Barbados 5
BF - Burkina Faso 5
PE - Perù 5
RS - Serbia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
DK - Danimarca 4
MD - Moldavia 4
MN - Mongolia 4
MT - Malta 4
NP - Nepal 4
OM - Oman 4
PT - Portogallo 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AO - Angola 3
CY - Cipro 3
GT - Guatemala 3
Totale 42.021
Salva come PNG Salva come JPEG
Città #
Singapore 2.592
Ashburn 1.725
Southend 1.642
Fairfield 1.282
Chandler 1.043
Hong Kong 979
San Jose 970
Ho Chi Minh City 826
Hanoi 716
Hefei 708
Santa Clara 696
Woodbridge 617
Houston 545
Seattle 542
Wilmington 538
Princeton 515
Beijing 445
Dong Ket 444
Cambridge 419
Council Bluffs 415
Dublin 409
Bologna 407
Ann Arbor 353
Boardman 336
Lauterbourg 297
Seoul 292
New York 287
Helsinki 273
Los Angeles 260
Jacksonville 250
Tokyo 230
Abidjan 207
Nanjing 201
Milan 183
Lomé 174
Westminster 174
Berlin 168
Padova 153
Buffalo 144
Frankfurt am Main 140
Sofia 133
Dallas 128
Bern 121
Amman 120
Da Nang 116
Haiphong 110
San Diego 108
São Paulo 107
Rome 98
Guangzhou 89
Redondo Beach 87
Turin 83
Bengaluru 80
Jinan 80
Shenyang 80
Phoenix 76
Saint Petersburg 76
Changsha 70
Brescia 65
Chicago 63
Johannesburg 62
Shanghai 61
Hebei 60
Munich 60
London 56
Washington 56
Nuremberg 55
Brussels 52
Redwood City 52
Atlanta 51
Mülheim 51
Orem 51
San Francisco 51
Yubileyny 51
Nanchang 50
Falkenstein 48
Montreal 48
Medford 42
Redmond 42
Bremen 41
Florence 40
Tianjin 40
Hải Dương 39
Warsaw 39
Dearborn 36
Quận Bình Thạnh 36
Des Moines 35
Henderson 34
Jiaxing 34
Mexico City 34
Thái Nguyên 34
Falls Church 33
Zhengzhou 33
Lappeenranta 32
Amsterdam 31
Biên Hòa 31
Hangzhou 30
Toronto 30
Boston 29
Brooklyn 29
Totale 26.206
Salva come PNG Salva come JPEG
Nome #
Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection 688
Ulcerative Colitis 378
Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study 363
COVID-19 in IBD: The experience of a single tertiary IBD center 311
Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil antibodies in coeliac disease before and after gluten free diet. 308
5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema 285
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment 279
A Heavy Feeling in the Stomach: Neural Correlates of Anxiety in Crohn's Disease 272
Adult attachment and early parental experiences in patients with Crohn’s Disease 265
5-Aminosalicylic acid suppositories in the management of ulcerative colitis 264
Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial 255
Absence of change in the gray matter volume of patients with ulcerative colitis in remission: a voxel based morphometry study 250
Can supplementation of phytoestrogens/insoluble fibers help the management of duodenal polyps in familial adenomatous polyposis? 248
Management of pouch dysfunction or pouchitis with an ileoanal pouch. 245
Adenocarcinoma in Crohn's disease: the pathologist's experience in a tertiary referral centre of inflammatory bowel disease. 242
A-Transducin, a Signaling Molecule of the Chemoreceptive Cascade, Is Expressed in Endocrine and Non-Endocrine Cells of the Pig Gastrointestinal Mucosa 239
Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis 238
Real-time elastography for the detection of fibrotic and inflammatory tissue in patients with stricturing Crohn's disease 234
Four cases of carcinoid tumour in Crohn's disease: coincidence or correlation? 229
Performance of Capsule Endoscopy and Cross-Sectional Techniques in Detecting Small Bowel Lesions in Patients with Crohn’s Disease 229
Medical treatment and management of severe ulcerative colitis 226
Distinct proteomic profiles characterise non-erosive from erosive reflux disease. 225
Cell proliferation of esophageal squamous epithelium in erosive and non-erosive reflux disease 223
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment 220
Probiotics, Prebiotics and Antibiotics in the Treatment of Inflammatory Bowel Disease 219
Infliximab in the treatment of Crohn's disease 218
Attachment and quality of life in patients with inflammatory bowel disease 218
Adalimumab in active ulcerative colitis: a "real-life" observational study. 216
Clinical management of severe active ulcerative colitis in the TNF-α inhibitors era 215
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations 215
High-dose probiotics for the treatment of active pouchitis 213
Short-term treatment with Infliximab in chronic refractory pouchitis and ileitis. 213
Influence of steroid treatment's duration in patients with active Crohn's disease 209
Percutaneous Drainage vs. Surgery as Definitive Treatment for Anastomotic Leak after Intestinal Resection in Patients with Crohn's Disease 208
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference 203
Cutaneous Manifestations in Inflammatory Bowel Diseases: Eight Cases of Psoriasis Induced by Anti-Tumor-Necrosis-Factor Antibody Therapy 202
Implications of the westernized diet in the onset and progression of IBD 202
Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease 201
MODULATION OF HUMAN DENDRITIC CELL PHENOTYPE AND FUNCTION BY PROBIOTIC BACTERIA 201
Adalimumab Clearance, rather than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically 200
Drug delivery by polymeric micelles: an in vitro and in vivo study to deliver lipophilic substances to colonocytes and selectively target inflamed colon 200
Implications of antioxidant enzymes in human gastric neoplasms 198
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis 196
Adalimumab in the Treatment of Perianal Crohn's Disease: A Single Center in 64 Patients 196
Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults 195
Clinical course of microscopic colitis in a single-center cohort study 193
Potential role of the cannabinoid receptor CB in the pathogenesis of erosive and non-erosive gastro-oesophageal reflux disease 193
Brain functional changes in patients with ulcerative colitis: a functional magnetic resonance imaging study on emotional processing 193
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. 191
Functional magnetic resonance imaging study reveals differences in the habituation to psychological stress in patients with Crohn's disease versus healthy controls 191
Percutaneous abdomino-pelvic abscess drainage in complicated Crohn’s disease 190
Nutritional Biomarkers for the Prediction of Response to Anti-TNF-α Therapy in Crohn's Disease: New Tools for New Approaches 190
Antibiotics and probiotics in treatment of inflammatory bowel disease 189
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. 188
Oral budesonide in the treatment of chronic refractory pouchitis. 188
Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis 188
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 188
Management and treatment of distal ulcerative colitis 188
Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. 188
Dietary Habits and Nutrient Deficiencies in a Cohort of European Crohn's Disease Adult Patients 187
Post COVID-19 irritable bowel syndrome 186
Management of inflammatory bowel disease: does rifaximin offer any promises 186
Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts 186
Review article: aminosalicylates for distal colitis 184
Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease Study. 183
P151 Characteristics of presentation and risk factors for early recurrence after strictureplasty for Crohn’s disease of the small bowel in the biological era 183
Probiotics in IBD: A critical review 183
Role of Biologics in refractory pouchitis 182
Parental Bonding and Inflammatory Bowel Disease 182
Role of conventional therapies in the era of biological treatment in Crohn's disease. 182
Differential Brain Structural and Functional Patterns in Crohn's Disease Patients are Associated with Different Disease Stages 181
Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production 179
ADALIMUMAB IN THE TREATMENT OF PERIANAL CROHN'S DISEASE: A SINGLE CENTER EXPERIENCE IN 64 PATIENTS 179
Clinical guidelines for the management of pouchitis 179
ADALIMUMAB IN THE TREATMENT OF PERIANAL CROHN'S DISEASE: LONG TERM RESULTS IN A SINGLE TERTIARY CENTRE 178
Medical Treatment of Ulcerative Colitis: does traditional therapy still have a role? 177
MANAGEMENT OF POUCHITIS 176
The role of Budesonide-MMX in active ulcerative colitis. 175
Pre-pouch ileitis 173
Antimicrobials in the management of inflammatory bowel disease 173
Oral Budesonide and low serum albumin levels at surgery are associated with a higher risk of postoperative intra-abdominal septic complications after primary ileocaecal resection for Crohn's disease: A retrospective analysis of 853 consecutive patients 172
Which therapies are advisable in pouchitis? 172
COMBINATION OF SURGICAL THERAPY AND LOCAL INJECTIONS OF ADALIMUMAB IN TREATEMENT OF COMPLEX PERIANAL CROHN'S DISEASE 172
P325 Risk factors for lymph node involvement in patients undergoing ileal pouch-anal anastomosis for ulcerative colitis complicated by colorectal cancer in the biological years 172
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease 171
Comparison of intestinal ultrasound, conventional enteroclysis, CT and MRI enteroclysis, surgical findings for determining complications in patients with Crohn's Disease 171
Local Injection of Infliximab for the Treatment of Perianal Crohn's Disease. 171
Is CMV DNAemia an early marker of CMV colitis in patients with active ulcerative colitis? 170
[Abdominal scintigraphy with leukocytes marked with indium-111 in Crohn disease: clinical importance and prognostic usefulness] 170
Sympathetic hyperactivity in patients with ulcerative colitis. 168
Sporadic small bowel tumors detected by capsule endoscopy in patients with occult gastrointestinal bleeding 168
OC.01.8 USE OF INFLIXIMAB AND ADALIMUMAB IN REFRACTORY POUCHITIS 167
Risks and Benefits of Mucosal Healing With Combined Immunosuppression in Paediatric Crohn's Disease: A Complex Topic That Needs Careful Evaluation 166
A current overview of corticosteroid use in active ulcerative colitis 166
Randomized controlled trials in pouchitis 165
Transabdominal salvage surgery after pouch failure in a tertiary center: a case-matched study 165
VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis 164
Topical treatment of distal active ulcerative colitis with beclometasone dipropionato or mesalamine: a single-blind randomized controlled trial 164
Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis 164
New insights into the brain involvement in patients with Crohn's disease: a voxel-based morphometry study 163
Totale 20.867
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.661
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.661
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.683 0 114 247 182 332 178 98 227 331 293 1.079 602
2022/20234.892 505 745 248 551 319 387 141 286 898 141 340 331
2023/20241.530 107 237 137 111 125 358 78 91 40 110 60 76
2024/20255.994 296 834 478 382 929 305 447 208 142 408 318 1.247
2025/202615.533 1.385 1.564 1.335 1.084 1.580 936 1.594 530 2.964 1.381 687 493
2026/20271.088 485 603 0 0 0 0 0 0 0 0 0 0
Totale 43.014